We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Cyteir Therapeutics Inc (CYT) USD0.001

Sell:$16.25 Buy:$16.56 Change: $0.06 (0.36%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$16.25
Buy:$16.56
Change: $0.06 (0.36%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$16.25
Buy:$16.56
Change: $0.06 (0.36%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing precision oncology medicines that inhibit deoxyribonucleic acid (DNA) damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality. The Company's pipeline includes CYT-0851 and CYT-1853. Its lead program, CYT-0851, is an oral, once-daily, small molecule inhibitor of RAD51-mediated homologous recombination (HR), a DNA repair pathway critical for the survival of some cancers. The Company is developing CYT-1853 as an inhibitor of RAD51-mediated HR.

Contact details

Address:
128 SPRING STREET, BUILDING A, SUITE 510
LEXINGTON
02421
United States
Telephone:
+1 (857) 2854140
Website:
cyteir.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CYT
ISIN:
US23284P1030
Market cap:
$489.53 million
Shares in issue:
35.37 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Markus Renschler
    President, Chief Executive Officer, Director
  • Paul Secrist
    Chief Scientific Officer
  • David Gaiero
    Vice President - Finance
  • Jean-Marc Lapierre
    Vice President - Chemistry
  • Barbara Wan
    Vice President - Research & Development, Project Leadership
  • Andrew Gengos
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.